Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trials in Los Angeles, California
3 recruitingLos Angeles, California
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 1Phase 2
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and Science99 enrolled1 locationNCT06615752
Recruiting
Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Gastric CancerNon-small Cell Lung Cancer (NSCLC)Head and Neck Squamous Cell Carcinoma+5 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674